Accurate Diagnosis and Personalized Treatment of NSCLC for the Interdisciplinary Team
The goal of this initiative is to provide guidance to the interdisciplinary NSCLC care team on how to develop practical testing protocols targeting genomic pathways for advanced non-small cell lung cancer (NSCLC) and how this information supports personalized treatment decisions for improved patient outcomes. It is essential that all members of the NSCLC care team understand the necessary processes and are equipped to apply current research on genomic targets to testing for mutations/drivers in appropriate advanced NSCLC patients.
Target Audience
This program is designed to meet the educational needs of oncologists, pulmonologists, pathologists, interventional radiologists, physician assistants, nurses, pharmacists, and other health care professionals involved in the care of patients with NSCLC.
Learning Objectives
Following this activity, participants should be able to:
- Employ effective biomarker screening processes to diagnose NSCLC associated with specific mutations
- Identify actionable oncogenic mutations associated with NSCLC and their implications for diagnosis and treatment
- Develop effective strategies for multidisciplinary management of NSCLC
NCCN Continuing Education Disclosure Policy
It is the policy of NCCN that every 12 months, all faculty, moderators, activity planners and all internal planning staff participating in NCCN continuing education activities are expected to disclose any financial relationships with a commercial interest. In addition, all faculty presentations have been reviewed to ensure education is fair and balanced and that clinical content presented supports safe, effective patient care. Individuals who do not disclose relevant financial relationships will be disqualified from involvement in the CE activity as a content developer, planner, or presenter.
Definitions
NCCN continuing education considers financial relationships to create a conflict of interest when an individual has both a financial relationship with a commercial interest and the opportunity to affect continuing education content about the products or services of a commercial interest with which he/she has a financial relationship.
NCCN continuing education considers relevant financial relationships as financial relationships in any amount occurring within the past 12 months that create a conflict of interest. NCCN does not set a minimal dollar amount for relationships to be significant. Inherent in any amount is the incentive to maintain or increase the value of the relationship.
Faculty Disclaimers
All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.
Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling.
Faculty Disclosures
The faculty listed below discloses no relevant financial relationships:
Kasey Bamel, DNP
Grace Lin, MD
The faculty listed below discloses the following relevant financial relationships:
Matthew A. Gubens, MD, MS
AstraZeneca Pharmaceuticals LP: Consulting Fee
Celgene Corporation: Grant/Research Support
Merck & Co., Inc.: Grant/Research Support
Novartis Pharmaceuticals Corporation: Grant/Research Support
OncoMed Pharmaceuticals: Grant/Research Support
Roche Laboratories, Inc./Genentech, Inc.: Grant/Research Support
sanofi-aventis U.S.: Consulting Fee
Trizell Ltd: Grant/Research Support
David Ost, MD
Intuitive Surgical, Inc.: Grant/Research Support
Sandip P. Patel, MD
AstraZeneca Pharmaceuticals LP: Scientific Advisor
AstraZeneca Pharmaceuticals LP/MedImmune Inc.: Grant/Research Support
Bristol-Myers Squibb Company: Grant/Research Support; Scientific Advisor
Eli Lilly and Company: Grant/Research Support; Scientific Advisor
Fate Therapeutics: Grant/Research Support
Genentech, Inc.: Scientific Advisor
Genocea Biosciences, Inc.: Grant/Research Support
Illumina, Inc.: Scientific Advisor
Incyte Corporation: Grant/Research Support
Iovance Biotherapeutics, Inc.: Grant/Research Support
Merck & Co., Inc.: Grant/Research Support
Paradigm Biopharmaceuticals Ltd: Scientific Advisor
Pfizer Inc.: Grant/Research Support
Rakuten Medical, Inc.: Scientific Advisor
Roche Laboratories, Inc./Genentech, Inc.: Grant/Research Support
Tempus Labs, Inc.: Scientific Advisor
Xcovery LLC: Grant/Research Support
Momen M. Wahidi, MD, MBA
Cook Medical LLC: Consulting Fee
Olympus Corporation of the Americas: Consulting Fee
Pulmonx Corporation: Consulting Fee
Staff Disclosures
The Activity Planning staff listed below discloses no relevant financial relationships:
NCCN: Kristina M. Gregory, RN, MSN, OCN; Kristin Kline Hasson; Karen Kanefield; Lisa Perfidio, MS; Kathy Ann Smith, CHCP
The France Foundation: Constance Kendros; Morghan Long; Heather Tarbox, MPH; Eve J. Wilson, PhD, CHCP, ELS
The NCCN Clinical staff listed below discloses no relevant financial relationships:
Miranda Hughes, PhD
In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physicians
NCCN designates this enduring activity for a maximum of 1.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurses
NCCN designates this educational activity for a maximum of 1.75 contact hours.
Pharmacists
NCCN designates this knowledge-based continuing education activity for 1.75 contact hours (0.175 CEUs) of continuing education credit. UAN: JA4008196-0000-21-041-H01-P
Physician Assistants
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.75 AAPA Category 1 CME credits. Approval is valid until May 6, 2022. PAs should only claim credit commensurate with the extent of their participation.
Available Credit
- 1.75 AAPA Category 1 CME credit
- 1.75 ACPE contact hours
- 1.75 AMA PRA Category 1 Credit™
- 1.75 ANCC contact hours
- 1.75 Participation
Price
Required Hardware/software
To complete this activity, users will need:
- A device with an Internet connection and sound playback capability
- One of the two latest versions of Google Chrome, Mozilla Firefox, or Safari
- Internet Explorer is no longer supported
- Adobe Reader or other PDF reader software for certificate viewing/printing